Phase 1a/1b Study of IGM-8444 Alone and in Combination in Subjects With Relapsed, Refractory, or Newly Diagnosed Cancers

ABSTRACT: This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of IGM-8444 as a single agent and in combination in subjects with relapsed and/or refractory solid or hematologic cancers, as well as newly diagnosed cancers, and an open-label, randomized study of IGM-8444+FOLFIRI (± bevacizumab).

DISEASE(S): Chronic Lymphocytic Leukemia,Chondrosarcoma,Acute Myeloid Leukemia,Solid Tumor,Sarcoma,Small Lymphocytic Lymphoma,Leukemia,Non Hodgkin Lymphoma,Colorectal Cancer,Leukemia, Lymphocytic, Chronic, B-cell,Lymphoma

PROVIDER: 2351929 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR